Our Focus Pipeline Elevation Oncology Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet medical needs in oncology In August 2025, Grupo Español Multidisciplinar de Melanoma announced a Phase II clinical trial designed to evaluate the activity of encorafenib plus binimetinib followed by cemiplimab and fianlimab in
Oncology Pipeline
Oncology Pipeline Much work has been published on artificial intelligence (AI) and oncology, with many focusing on an algorithm perspective However, very few perspective articles have explicitly discussed the role of DS 6157: Daiichi Sankyo Company DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline and a deep understanding of the life sciences and Here are some of the largest recent moves: FMR LLC added 5,598,190 shares (+7978%) to their portfolio in Q3 2024, for an estimated $664,897,026 HARDING LOEVNER LP removed 2,924,436 shares (-999% NORTH CHICAGO, Ill, March 26, 2025 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the
Oncology Pipeline
Oncology Pipeline Here are some of the largest recent moves: FMR LLC added 5,598,190 shares (+7978%) to their portfolio in Q3 2024, for an estimated $664,897,026 HARDING LOEVNER LP removed 2,924,436 shares (-999% NORTH CHICAGO, Ill, March 26, 2025 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that new data from its early oncology research will be showcased across multiple presentations at the In August 2025, H Lee Moffitt Cancer Center and Research Institute announced a study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated Eight researchers specializing in adult oncology from Fred Hutch Cancer Center and the University of Washington have been awarded a total of $7,268,202 from the Kuni Foundation’s Discovery Grant CAMBRIDGE, Mass, Aug 20, 2025 /PRNewswire/ -- XtalPi announced on the 20 th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential See why I rate PFE stock a Buy
Oncology Pipeline
Oncology Pipeline In August 2025, H Lee Moffitt Cancer Center and Research Institute announced a study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated Eight researchers specializing in adult oncology from Fred Hutch Cancer Center and the University of Washington have been awarded a total of $7,268,202 from the Kuni Foundation’s Discovery Grant CAMBRIDGE, Mass, Aug 20, 2025 /PRNewswire/ -- XtalPi announced on the 20 th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential See why I rate PFE stock a Buy
Comments are closed.